Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.57 |
| ▸ | PGR | P06401 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634863 | 0.82 | NR3C1 (0.70) | NR3C1NR3C2PGR | |
| SCHEMBL1633701 | 0.79 | NR3C1 (0.72) | NR3C1NR3C2PGR | |
| SCHEMBL1634559 | 0.77 | NR3C1 (0.69) | NR3C1NR3C2PGR | |
| SCHEMBL292256 | 0.76 | NR3C1 (0.74) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL1634911 | 0.76 | NR3C1 (0.67) | NR3C1NR3C2PGR | |
| SCHEMBL1634849 | 0.76 | NR3C1 (0.71) | NR3C1NR3C2PGR | |
| SCHEMBL15746607 | 0.76 | NR3C1 (0.74) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL15756243 | 0.75 | NR3C1 (0.60) | NR3C1NR3C2PGR | |
| SCHEMBL15756258 | 0.75 | NR3C1 (0.67) | NR3C1NR3C2PGR | |
| SCHEMBL292918 | 0.75 | NR3C1 (0.65) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | SOLTA MEDICAL, INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | PTGIR, NR3C1, PTGDR | NR3C1 2/4885NR3C2 11/4885PGR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.